Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial
Indian Journal of Dermatology, Venereology and Leprology · 09.04.2022 · 89 · 195-203
DOI: 10.25259/ijdvl_1011_20 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 09.04.2022. Verfasst von Reham Ezz El-Dawla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt. Hauptthemen laut MEDLINE: Alopecia Areata, Platelet-Rich Plasma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic telogen effluvium is characterised by diffuse loss of hair of the scalp. One of the emerging lines of treatment is platelet-rich plasma. However, not much of published data exist.
Aims
A pilot study was conducted on chronic telogen effluvium patients to evaluate the efficacy and safety of platelet-rich plasma, and to compare two different methods of platelet-rich plasma preparation.
Methods
The study included 30 female patients with chronic telogen effluvium. Patients were randomised into three groups: Group (1): Special platelet-rich plasma tubes centrifuged at 3500 rpm; Group (2): Ordinary laboratory tubes centrifuged at 1000 rpm; Group (3): Normal saline as a placebo. Patients' evaluation was done with visual analog scale, hair pull test, trichoscopy, photos, satisfaction questionnaire, and safety. All patients received four monthly sessions. Patients were evaluated one month and three months after the last session.
Results
The hair pull test,visual analogue scale, and patient satisfaction results showed a statistically significant difference between group 1 vs. group 3 and group 2 vs.group 3 at one and three months after the sessions, while there was no difference between group1 vs. group 2. Trichoscopy results (baseline, one and three months after treatment) showed a significant increase in hair density and thickness in the frontal area, temporal area, and the vertex in groups 1 and 2 only. There was no statistically significant difference between the three groups with regards to side effects.
Limitations
The sample size was small with ten patients in each group. Furthermore, the follow-up of patients was for only three months.
Conclusions
Platelet-rich plasma could be considered as a promising therapy for patients with chronic telogen effluvium with an excellent safety profile. The ordinary laboratory low-cost tubes might be a reliable alternative to the expensive special platelet-rich plasma kits tubes. The trial registry number is PACTR202006539654415.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Zitieren
APA
El-Dawla, R. E., Abdelhaleem, M., & Abdelhamed, A. (2022). Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial. Indian Journal of Dermatology, Venereology and Leprology, 89, 195-203. https://doi.org/10.25259/ijdvl_1011_20
Vancouver
El-Dawla RE, Abdelhaleem M, Abdelhamed A. Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial. Indian Journal of Dermatology, Venereology and Leprology. 2022;89:195-203. doi:10.25259/ijdvl_1011_20
BibTeX
@article{ElDawla2022,
author = {El-Dawla, Reham Ezz and Abdelhaleem, Maryam and Abdelhamed, Amr},
title = {Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2022},
volume = {89},
pages = {195--203},
doi = {10.25259/ijdvl_1011_20}
}
EUVIMED